Subscribe to The Free Market Chronicle and join the 2,679 subscribers getting it for FREE!

[widget id=”wordads_sidebar_widget-41″]

Acadia and Facebook Rise, Twitter Slumps, More To Come

[widget id=”text-16″]

The stock market continues its advance in 2018, and this time it was the Biotech group that led the market higher after Celgene announced it was acquiring Juno, and Sanofi buying Bioverativ. It led a massive breakout in the group, the one we had been eagerly waiting for and talking about happening. Today we take a look at Acadia, Twitter, and Facebook

[vc_tweetmeme type=”follow” follow_user=”michaelmottcm” show_followers_count=”true” large_button=”true”]

Join our 2,679 Daily Subscribers And Get This Commentary In Your E-Mail!

Acadia

Acadia Pharmaceuticals even managed to show some signs of life, with the stock rising by nearly 8 percent on the day. Shares have not broken out, so don’t get too excited yet, but they are surely nearing one. We can see how close that breakout came and it will not take much of a follow-through tomorrow to see that breakout happen.

Facebook

Facebook shares took another step to recouping those losses after the news feed revamp. Shares are approaching $188, and it will be essential to see how the stock responses when it gets there. Will it fill the gap and move lower, or will it continue to rise?

Volume has been strong, and well above the 3-month moving average, while the relative strength index is nowhere near overbought or oversold. Plus the stock also has the benefit of a strong stock market, and more importantly a healthy technology sector. It would seem a rise to $188, and above is likely coming.

[widget id=”text-17″]

Twitter

Twitter shares appear to be in an interesting scenario and on the cusp of a reasonably significant breakdown. The chart below shows how the stock has broken a critical uptrend, which dates back to mid-October. But it also sits on a considerable support level as well.

Should Twitter’s stock fail and fall below $23, it seems the stock could be on its way lower back to $18.

Back later with Netflix.

[widget id=”text-13″]

Mott Capital’s Reading The Markets – An In-depth Global Macro Stock Market Commentary – In Video Format – See How Michael Dissects The Markets

Just $200 Per Year – Get Your Free Trial

Why Apple’s Suppliers Are Plunging As Mega Tech Thrives

Why A Rising Stock Market Isn’t Risky

Netflix Investors May Be Getting Too Bullish On The Stock

Why Chipmaker Lam Research Is Poised For a Rebound

How a Juno Takeover Could Boost Celgene

Why Ford Could Rise By Nearly 30%

Why Morgan Stanley’s Stock Is Poised to Rise by 25%

Apple Poised to Gain 14%, Defying Skeptics

Exxon Mobil May Rise 20% on the Back of Surging Oil

We offer daily market commentaries sent directly to your inbox or follow us on Twitter.

Join our 2,679 Daily Subscribers And Get This Commentary In Your E-Mail! Subscribe

-OR-

[vc_tweetmeme type=”follow” follow_user=”michaelmottcm” show_followers_count=”true” large_button=”true”]

Photo Credit Via Flickr

Michael Kramer and the clients of Mott Capital own shares of ACAD, CELG

Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future.

Tags: #sp500 #biotech #facebook #twitter #acadia